Three-dimensional psoas muscle volume and longitudinal changes as predictors of outcomes in older patients with advanced pancreatic cancer

Table 2 Treatment efficacy and treatment course in the sarcopenic and non-sarcopenic patients, median (range)/n (%)

Variable	Sarcopenic patients	Non-sarcopenic patients	P value
Patients,	46 (30.7)	104 (69.3)
Completion rate of GnP
Until one cycle	65.2 (30/46)	99.0 (103/104)	< 0.001
Until two cycles	51.2 (22/43)	94.1 (96/102)	< 0.001
Treatment response (n = 143)
Objective response rate	9.1 (4/44)	19.2 (19/99)	0.147
Disease control rate	43.2 (19/44)	87.9 (87/99)	< 0.001
Relative dose intensity, %
Until the first one cycle
Gemcitabine	80.7 (50.5-101.3)	81.8 (41.5-103.7)	0.966
Nab-paclitaxel	80.6 (51.5-99.0)	81.4 (39.8-103.7)	0.934
Until the first two cycles (n = 126)
Gemcitabine	79.6 (63.4-96.8)	80.6 (47.1-102.4)	0.758
Nab-paclitaxel	79.7 (58.3-99.0)	79.8 (48.4-102.4)	0.712
Treatment after GnP (n = 96)			0.004
Second-line therapy after GnP	17 (45.9)	45 (76.3)
FOLFIRINOX	3 (8.1)	21 (35.6)
Nal-IRI plus 5-FU/LV	4 (10.8)	9 (15.3)
Gemcitabine monotherapy	3 (8.1)	3 (5.1)
TS-1 monotherapy	6 (16.2)	10 (16.9)
TS-1 plus radiotherapy	1 (2.7)	2 (3.4)
Best supportive care	20 (54.1)	14 (23.7)

GnP: Gemcitabine plus nab-paclitaxel; Nal-IRI: Nanoliposomal irinotecan; 5-FU/LV: 5-Fluorouracil/Leucovorin; TS-1: Titanium silicate zeolite.